Target mechanisms may be represented by a reduction of IGF-1 levels and insulin levels in older cancer survivors, and an increase in IGFBPs levels60, the suppression of IGF-1/ER signaling pathway crosstalk, and the modulation of stromal IGF-1 interaction in the tumor microenvironment. The gene discussed is IGF1; the disease is cancer.